Lexitas Around The Web

How Allgenesis Evaluated Unique Endpoints to Advance its Phase

In this webinar, Sally Tucker, President of Global Services for Lexitas, is joined by the leadership team of Voxeleron and Allgenesis to discuss their collaboration on a recent Phase 2 study for diabetic macular edema (DME). The panelists highlight the importance of imaging and biomarkers in ophthalmology clinical trials and share their experiences working with […]

From Patient Care to Research: Dr. Bruce Segal’s Journey with Ophthalmic Drug Approval

Welcome back to the Inside Look podcast series, hosted by Dr. Andrew Pucker, Executive Director of Clinical & Medical Sciences at Lexitas Pharma Services. In this episode, Dr. Pucker sits down with Dr. Bruce Segal, an experienced ophthalmologist based in Delray Beach, Florida, to delve into the world of medical research and ophthalmic drug approval. […]

The Impact of Contact Lens Wear On the Ocular Surface w/ Dr. Joe Shovlin

In this episode of the Inside Look podcast series, host Dr. Andrew Pucker is joined by Dr. Joe Shovlin to discuss the impact of contact lens wear on the ocular surface. The conversation revolved around a paper from the Tear Film and Ocular Surface Society (TFOS) titled “Impact of Contact Lenses on the Ocular Surface”. […]

Lifestyle Impact On Ocular Health w/ Dr. Sheetal Shah

In this episode of the Inside Look podcast series, Dr. Sheetal Shah, a Cornea, and External Disease Specialist, sits with Dr. Andrew Pucker, Executive Director of Clinical and Medical Sciences at Lexitas Pharma Services, to discuss lifestyle impacts on ocular health and how cosmetics can impact the ocular surface. They delve into the findings of […]

How Exonate Plans to Revolutionize Diabetic Eye Disease Treatment: A Convo with Dr. Catherine Beech

In this episode of Inside Look, Julie Schlosser sits down with Dr. Catherine Beech, CEO of biotech company Exonate, to discuss their cutting-edge work in ophthalmology. Exonate is focused on developing a groundbreaking eye drop treatment for diabetic eye disease, aiming to replace the need for invasive injections into the eye. Dr. Beech shares the […]

Best-Corrected Visual Acuity Testing In Clinical Practice and Clinical Trials

Congrats to Drs. Winston Posvar and Andrew D. Pucker, OD, PhD, for being published in The Ophthalmologist with their article summarizing the pros and cons of visual acuity testing. Learn how Snellen and ETDRS methods are best utilized in clinical trials. Check Out More

The Future Of Decentralized Clinical Trials In Ophthalmology

In decentralized clinical trials (DCTs), investigators reduce dependence on intermediary specialists and traditional facilities for data acquisition by using virtual elements to facilitate treatment and data collection in a subject’s home.1 As clinical trials shift toward a more decentralized model, telemedicine is poised to play a more substantial role. Check out more

Trends in Ophthalmology Clinical Trials (Video)

Ophthalmic clinical trials are increasing in complexity, as novel endpoints, new innovations in gene therapy and advances in AI are helping to push the boundaries of what was previously possible. Listen to CRO experts in clinical operations and ophthalmology talk about the trends and opportunities in clinical studies for eye disease. Our Visionary Insights newsletter is published […]

The State of the Ophthalmology Funding Landscape

Lexitas Pharma Services CEO and Executive Chairwoman Jeanne Hecht joins Triangle Business Journal President and Publisher Jason Christie to talk about Lexitas’ recent growth and where it’s headed as the new year approaches. See More Our Visionary Insights newsletter is published once a month and has thousands of subscribers. To stay in touch, subscribe today.

A Deeper Look at Pegcetacoplan (via Optometry Times Journal)

The US Food and Drug Administration (FDA) approved pegcetacoplan (Syfovre; Apellis Pharmaceuticals) in February 2023 for the treatment of geographic atrophy (GA) in patients with advanced age-related macular degeneration (AMD), and now, for the first time, the community has a treatment option for dry AMD beyond vitamins. Pegcetacoplan is an intravitreal drug and, unlike anti-VEGF (vascular endothelial growth factor) injections, it […]